Patrick Michael Flanigan

Patrick Michael Flanigan

Auto-generated profile, based on publicly available information

Patrick Michael Flanigan

UCSF , San Francisco, CA , USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Neurosurgery
Verified
Journal Article
Open access
PDF file
AJArman Jahangiri
Arman Jahangiri
ACAaron T. Chin
Aaron T. Chin
PFPatrick M. Flanigan
Patrick M. Flanigan
RCRebecca Chen
Rebecca Chen
KBKrystof Bankiewicz
Krystof Bankiewicz
MAManish K. Aghi
Manish K. Aghi
Glioblastoma is the most common malignant brain tumor, and it carries an extremely poor prognosis. Attempts to develop targeted therapies have been hindered because the blood-brain barrier prevents many drugs from reaching tumors cells. Furthermore, systemic toxicity of drugs often limits their therapeutic potential. A number of alternative methods of delivery have been developed, one of which is convection-enhanced delivery (CED), the focus of this review. The authors describe CED as a therapeutic measure and review preclinical studies and the most prominent clinical trials of CED in the treatment of glioblastoma. The utilization of this technique for the delivery of a variety of agents is covered, and its shortcomings and challenges are discussed in detail.

20 February 2017 in Oncogene
Verified
Journal Article
Open access
PDF file
BCB A Castro
B A Castro
PFP Flanigan
P Flanigan
AJA Jahangiri
A Jahangiri
DHD Hoffman
D Hoffman
WCW Chen
W Chen
MAManish K. Aghi
Manish K. Aghi
Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the tumor microenvironment. We confirmed increased tumor-associated macrophages in bevacizumab-resistant glioblastoma patient specimens and two novel glioblastoma xenograft models of bevacizumab resistance. Microarray analysis suggested downregulated macrophage migration inhibitory factor (MIF) to be the most pertinent mediator of increased macrophages. Bevacizumab-resistant patient glioblastomas and both novel xenograft models of resistance had less MIF than bevacizumab-naive tumors, and harbored more M2/protumoral macrophages that specifically localized to the tumor edge. Xenografts expressing MIF-shRNA grew more rapidly with greater angiogenesis and had macrophages localizing to the tumor edge which were more prevalent and proliferative, and displayed M2 polarization, whereas bevacizumab-resistant xenografts transduced to upregulate MIF exhibited the opposite changes. Bone marrow-derived macrophage were polarized to an M2 phenotype in the presence of condition-media derived from bevacizumab-resistant xenograft-derived cells, while recombinant MIF drove M1 polarization. Media from macrophages exposed to bevacizumab-resistant tumor cell conditioned media increased glioma cell proliferation compared with media from macrophages exposed to bevacizumab-responsive tumor cell media, suggesting that macrophage polarization in bevacizumab-resistant xenografts is the source of their aggressive biology and results from a secreted factor. Two mechanisms of bevacizumab-induced MIF reduction were identified: (1) bevacizumab bound MIF and blocked MIF-induced M1 polarization of macrophages; and (2) VEGF increased glioma MIF production in a VEGFR2-dependent manner, suggesting that bevacizumab-induced VEGF depletion would downregulate MIF. Site-directed biopsies revealed enriched MIF and VEGF at the enhancing edge in bevacizumab-naive patients. This MIF enrichment was lost in bevacizumab-resistant glioblastomas, driving a tumor edge M1-to-M2 transition. Thus, bevacizumab resistance is driven by reduced MIF at the tumor edge causing proliferative expansion of M2 macrophages, which in turn promotes tumor growth.


26 September 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AJArman Jahangiri
Arman Jahangiri
ANAlan Nguyen
Alan Nguyen
ACAnkush Chandra
Ankush Chandra
MSMaxim K. Sidorov
Maxim K. Sidorov
GYGarima Yagnik
Garima Yagnik
MAManish K. Aghi
Manish K. Aghi
Significance: Invasion is a major cause of cancer mortality, as exemplified by metastatic spread of peripheral malignancies or local intracranial invasion of glioblastoma. While individual mediators of invasion are identified, functional or structural interactions between these mediators remain undefined. We identified a structural cross-activating c-Met/β1 integrin complex that promotes breast cancer metastases and invasive resistance of glioblastoma to the antiangiogenic therapy bevacizumab. We show that tumor cells adapt to their microenvironmental stressors by usurping c-Met and β1 integrin, with c-Met displacing α5 integrin from β1 integrin to form a c-Met/β1 complex with far greater fibronectin affinity than α5β1 integrin. These findings challenge conventional thinking about integrin–ligand interactions and define a molecular target for disrupting metastases or invasive oncologic resistance.

1 September 2015 in Epilepsy Research
Verified
Journal Article
Closed access
BLBradley Lega
Bradley Lega
SDSasha Dionisio
Sasha Dionisio
PFPatrick Flanigan
Patrick Flanigan
WBWilliam Bingaman
William Bingaman
INImad Najm
Imad Najm
JGJorge Gonzalez-Martinez
Jorge Gonzalez-Martinez

1 October 2016 in Journal of Food Composition and Analysis
Verified
Journal Article
Closed access
Katherine Raenah McCanceKatherine Raenah McCance
Katherine Raenah McCance
PFPatrick M. Flanigan
Patrick M. Flanigan
MQM. Montana Quick
M. Montana Quick
ENEmily D. Niemeyer
Emily D. Niemeyer